The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa377. doi: 10.1093/ofid/ofaa377.eCollection 2020 Oct.
Brianna L Norton1, Matthew J Akiyama1, Linda Agyemang1, Moonseong Heo2, Irene- Pericot-Valverde3, Alain H Litwin345
Author information
1Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
2Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA.
3Department of Medicine, University of South Carolina School of Medicine - Greenville, Greenville, South Carolina, USA.
4Clemson University School of Health Research, Clemson, South Carolina, USA.
5Prisma Health, Greenville, South Carolina, USA.
Abstract
We measured hepatitis C virus (HCV) adherence via electronic blister packs for 145 people who inject drugs treated on-site in a methadone program. The overall sustained virologic response (SVR) rate was 96% (95% CI, 91%-98%), and overall daily adherence was 78% (95% CI, 76%-81%). Participants who achieved at least 50% adherence had an overall SVR rate of 99%, with each 5% adherence interval >50% achieving at least 90% adherence. Suboptimal adherence may still lead to cure in the direct-acting antiviral era.